Booth No. : A32
Presentation Representative : Masaru Tomita
Person in Charge of the Project : Masaru Tomita
We have developed a novel technology for high-throughput metabolome analysis, which can simultaneously quantify a large amount of metabolites.
Based on this technology, we founded Human Metabolome Technologies, Inc. (HMT), and the company was listed on the Tokyo Stock Exchange Mothers in December, 2013.
Using this technology, HMT has discovered a biomarker of major depression, Ethanolamine Phosphate (EAP), and is trying to make the diagnostic service commercial world-wide.
